Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

ZYUS Life Sciences Clears Phase 2a Enrollment Hurdle as Capital Constraints Persist

By The Northwire Desk — AI Analysis Apr 16, 2026 · 07:00 ZYUS · 0.5 ZYUS Life Sciences Corporation
Executive Summary
  • ZYUS Life Sciences announced the completion of the final study visit ("Last Patient Last Visit") for its Phase 2a UTOPIA-1 clinical trial.
  • The trial evaluates Trichomylin® softgel capsules for moderate to severe cancer-related pain.
  • Top-line results are expected in Q2 2026 following data cleaning and analysis.
  • This follows preliminary positive safety/efficacy signals reported in January 2026 from the first cohort of patients.
  • The milestone confirms operational progress but does not yet provide definitive clinical efficacy data required for regulatory approval or commercialization discussions.
Material Impact
  • Impact Level: Routine - Positive. While completing a trial is a necessary step, it was anticipated following enrollment milestones reported in late 2025 and early 2026.
  • Market Expectation: The market has already priced in the financing difficulties (cancellation of $15M offering in February) which caused the stock to decline from ~$0.70 in January to $0.50 by April.
  • Catalyst Timing: The material catalyst remains the Q2 2026 top-line results, not the enrollment completion itself. Investors typically react more strongly to data readouts than operational milestones at this stage.
  • Comparison to History: This news is consistent with the trajectory set in January (preliminary data) and October/November (site expansion). It does not introduce new financial or strategic surprises compared to the financing cancellations earlier in 2026.
ZYUS · Price
Company Overview
  • Company: ZYUS Life Sciences Corp., trading on TSX Venture Exchange (Ticker: ZYUS).
  • Flagship Project: Trichomylin® softgel capsules, a novel non-opioid drug candidate for cancer-related pain.
  • Development Stage: Phase 2a UTOPIA-1 trial completed enrollment; awaiting top-line results in Q2 2026.
  • Mechanism of Action: Aims to provide analgesic efficacy with opioid-sparing effects, addressing the unmet need for non-opioid pain management in oncology patients.
Read the original news release →

More from ZYUS Life Sciences Corporation

Jun 24, 2026 · 20:46

Clinical-stage biotech secures incremental insider debt to fund working capital amid Phase 2a trial completion and filing delays.

Financings Jun 17, 2026 · 21:12

Clinical-stage biotech secures incremental working capital amid filing delays and strategic pivot to core pain pipeline.

Financings Jun 11, 2026 · 16:30

Streamlining operations and shedding non-core assets to preserve cash ahead of critical Phase 2a data readout amid regulatory filing delays.

Production / Operations May 28, 2026 · 00:11

ZYUS Slides into Limbo as Cease Trade Order Grinds Operations, While a Trickle of Insider Loans Can’t Mask a Race Against Time

Financings May 20, 2026 · 22:30

ZYUS Life Sciences Struggles with Regulatory Compliance Amidst Liquidity Crunch

Financings May 05, 2026 · 18:00

Patent Grant Offers IP Shield Amidst Liquidity Crunch and Regulatory Filing Delays

Other